Virtual Symposium: The Evolving Landscape of LDL-C Reduction: Novel Therapies and Approaches

Lowering LDL-C effectively and safely is crucial in preventing ASCVD events. Even with the advances in LDL-C-lowering therapy, there is considerable residual risk due to suboptimal adherence, clinical efficacy, or clinical inertia, which increases the chances of serious adverse CV events. Several new and emerging agents may help address these gaps in the near future, and clinicians need to be aware of these new approaches and their potential role in the treatment of high-risk patients with elevated LDL-C.

During this recorded symposium from the 2020 CMHC West meeting, expert faculty will overview the data and the clinical practice implications of these new and emerging agents in order to enhance their clinical utility and optimize patient outcomes.


I. A Contemporary Overview of Lipid Lowering Therapy in 2020: Can Newer Therapeutics Address Old Challenges?
Salim S. Virani, MD, PhD, FASPC, FACC, FAHA

II. Novel Agents for LDL Lowering and Patient Case
Pam R. Taub, MD, FACC

III. Audience Q&A
Christie M. Ballantyne, MD; Pam R. Taub, MD, FACC; Salim S. Virani, MD, PhD, FASPC, FACC, FAHA

IV. Additional Resources

Target Audience

This activity is designed for US-based healthcare professionals, including primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, and other allied health professionals.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Recognize residual ASCVD risk that may persist even after maximally-tolerated LDL-C lowering agents.
  • Identify high-risk patients with elevated LDL-C and ASCVD who may not adequately respond or adhere to current therapy.
  • Review the rationale, mechanisms of action, efficacy and safety of LDL-C lowering agents in advanced clinical development and their potential role in hypercholesterolemia management and ASCVD risk reduction.
Course summary
Available credit: 
  • 1.25 ACPE Pharmacy
  • 1.25 AMA PRA Category 1 Credit
  • 1.20 ANCC
  • 1.50 CDE
  • 1.25 Participation
Course opens: 
Course expires: 

Christie M. Ballantyne, MD (Chair)
Professor of Medicine
Chief, Section of Cardiovascular Research
Chief, Section of Cardiology
Department of Medicine, Baylor College of Medicine
Director, Center for Cardiovascular Disease Prevention
Baylor College of Medicine
Methodist DeBakey Heart Center
Houston, TX

Dr. Ballantyne discloses the following: 

  • Grant/Research Support:  All significant. (All paid to institution, not individual): Abbott Diagnostic, Akcea, Amgen, Esperion, Novartis, Regeneron, Roche Diagnostic, NIH, AHA, ADA.
  • Consultant: Abbott Diagnostics, Akcea, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Corvidia, Denka Seiken, Esperion, Intercept, Janssen, Matinas Bio Pharma Inc., Merck, Novartis, Novo Nordisk, Regeneron*, Roche Diagnostic, Sanofi-Synthelabo*
  • *Significant where noted ($10,000); remainder modest (<$10,000)


Pam R. Taub, MD, FACC
Associate Professor of Medicine
Director of Step Family Foundation Cardiovascular Rehabilitation and Wellness Center
UC San Diego Health System
Division of Cardiovascular Medicine
La Jolla, CA

Dr. Taub discloses the following: 

  • Consulting Fees: Sanofi/Regeneron, Novo-Nordisk, Boehringer-Ingelheim, Janssen, Amgen, Pfizer, and Amarin
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest: Sanofi/Regeneron, Novo-Nordisk, Boehringer-Ingelheim, Janssen, Amgen, Pfizer, and Amarin


Salim S. Virani, MD, PhD, FACC, FAHA
Associate Professor, Section of Cardiovascular Research
Director, Cardiovascular Disease Fellowship Training Program
Baylor College of Medicine
Staff Cardiologist, Michael E. DeBakey Veterans Affairs Medical Center
Investigator, Health Policy, Quality and Informatics Program
Michael E. DeBakey Veterans Affairs Medical Center HSR&D Center for Innovations
Houston, TX

Dr. Virani discloses the following: 

  • Other: Honorarium: American College of Cardiology (Associate Editor for Innovations,

Supported by an educational grant from Esperion Therapeutics, Inc. 

image   image   image

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.2 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate. 

Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (.125 CEUs) of the Accreditation Council for Pharmacy Education.

This is an knowledged-based activity. Universal Activity Numbers (UAN): #JA4008162-9999-20-2266-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Postgraduate Institute for Medicine (CDR Provider #3631) is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.5 Continuing Professional Education units (CPEUs) for completion of this activity.

This is a Level II activity.

Evaluation of the quality of this activity/education materials may be submitted directly to CDR at

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) maintenance of certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The PIM planners and managers have nothing to disclose. The CMHC planners and managers have nothing to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

During the period August 28, 2020 through August 28, 2021, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at

For questions about the accreditation of this activity, please visit

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

Available Credit

  • 1.25 ACPE Pharmacy
  • 1.25 AMA PRA Category 1 Credit
  • 1.20 ANCC
  • 1.50 CDE
  • 1.25 Participation
Please login or register to take this course.

Required Hardware/software

This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not have these browsers, you can download Chrome here, Firefox here and Internet Explorer here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB RAM.